Commentary: Wogonoside alleviates metabolic dysfunction-associated steatohepatitis by modulating AMPK and xCT/GPX4 pathways to restrain lipid dysregulation and ferroptosis

Yuchen Fang, Lianjun Xing

Open source

DOI
10.3389/fphar.2026.1965553
Published
2026-10-21
Container
Frontiers in Pharmacology
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1965553,
  title = {Commentary: Wogonoside alleviates metabolic dysfunction-associated steatohepatitis by modulating AMPK and xCT/GPX4 pathways to restrain lipid dysregulation and ferroptosis},
  author = {Yuchen Fang and Lianjun Xing},
  year = {2026},
  journal = {Frontiers in Pharmacology},
  doi = {10.3389/fphar.2026.1965553},
  url = {https://doi.org/10.3389/fphar.2026.1965553}
}

RIS

TY  - JOUR
TI  - Commentary: Wogonoside alleviates metabolic dysfunction-associated steatohepatitis by modulating AMPK and xCT/GPX4 pathways to restrain lipid dysregulation and ferroptosis
AU  - Yuchen Fang
AU  - Lianjun Xing
PY  - 2026
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2026.1965553
UR  - https://doi.org/10.3389/fphar.2026.1965553
ER  - 

APA

Fang, Y., & Xing, L. (2026). Commentary: Wogonoside alleviates metabolic dysfunction-associated steatohepatitis by modulating AMPK and xCT/GPX4 pathways to restrain lipid dysregulation and ferroptosis. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2026.1965553

Source records